← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Steadman Philippon Research Institute
Vail, CO
$10,795,951
Total funding
10
Grants
Funding over time
peak $3.6M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,832,974 · 8
DOD$2,962,977 · 2
By mechanism
R01$3,995,311 · 3
—$2,962,977 · 2
UH3$2,563,053 · 1
R21$752,322 · 3
UG3$522,288 · 1
Investigators at Steadman Philippon Research Institute
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
THE USE OF SENOLYTIC AGENT TO IMPROVE THE BENEFIT OF PLATELET-RICH PLASMA AND LOSARTAN FOR TREATMENT OF FEMOROACETABULAR IMPINGEMENT AND LABRAL TEAR: A PILOT STUDY$2,000,000
· FY2021 · Department of the Navy
STRATEGIES FOR IMPROVING THE QUALITY AND EFFICACY OF AUTOLOGOUS EXTRACELLULAR VESICLES FOR TREATING MUSCULOSKELETAL INJURIES AND DISEASE$962,977
· FY2025 · Defense Health Agency
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis$633,825
UH3 · FY2021 · AR
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis$621,091
UH3 · FY2022 · AR
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis$600,051
UH3 · FY2023 · AR
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis$551,586
UH3 · FY2024 · AR
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis$522,288
UG3 · FY2020 · AR
Improved Tools for Accessing Pain Following Fracture and Enabling Standardized Pain Phenotyping$516,399
R01 · FY2023 · AR
Therapeutic Application of Painless Nerve Growth Factor to Accelerate Endochondral Fracture Repair$482,568
R01 · FY2021 · AR
Therapeutic Application of Painless Nerve Growth Factor to Accelerate Endochondral Fracture Repair$456,098
R01 · FY2023 · AR
Therapeutic Application of Painless Nerve Growth Factor to Accelerate Endochondral Fracture Repair$431,827
R01 · FY2022 · AR
Articular Cartilage Tissue Engineering with Human Pluripotent Stem Cells$344,300
R01 · FY2023 · AR
Bone Abmormalities and Healing Defect in Muscular Dystrophy$344,300
R01 · FY2018 · AR
Articular Cartilage Tissue Engineering with Human Pluripotent Stem Cells$344,300
R01 · FY2021 · AR
Articular Cartilage Tissue Engineering with Human Pluripotent Stem Cells$340,857
R01 · FY2022 · AR
Articular Cartilage Tissue Engineering with Human Pluripotent Stem Cells$333,971
R01 · FY2024 · AR
Articular Cartilage Tissue Engineering with Human Pluripotent Stem Cells$309,870
R01 · FY2025 · AR
SMART stem cells that autonomously down-modulate TFG-β signaling for Articular Cartilage Repair$220,903
R21 · FY2022 · AR
Muscle Stem Cells Reprogrammed Through Genome Engineering for Autonomously Regulated Anti-Fibrotic Therapy$204,154
R21 · FY2019 · AR
Effects of Circulating Factors and Progenitors on Wound Healing during Pregnancy$172,150
R21 · FY2019 · AR